揭示乙肝e抗原（HBeAg）血清学转换背后的免疫生物标志物：需要更多的转化研究。 - Suppr

Suppr

超能文献

Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: a need for more translational study.

作者信息

Lau George K K, Wang Fu-Sheng

出版信息

J Hepatol. 2012 Apr;56(4):753-5. doi: 10.1016/j.jhep.2011.12.006. Epub 2012 Jan 8.

DOI:10.1016/j.jhep.2011.12.006

PMID:22230868

Abstract

摘要

相似文献

Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: a need for more translational study.

J Hepatol. 2012 Apr;56(4):753-5. doi: 10.1016/j.jhep.2011.12.006. Epub 2012 Jan 8.

High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.

J Hepatol. 2012 Apr;56(4):775-81. doi: 10.1016/j.jhep.2011.10.020. Epub 2011 Dec 13.

Treatment with nucleos(t)ide analogues in chronic hepatitis B: where does the road map lead us?

J Hepatol. 2009 Jul;51(1):1-3. doi: 10.1016/j.jhep.2009.04.007. Epub 2009 May 3.

[Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].

Zhonghua Gan Zang Bing Za Zhi. 2011 Mar;19(3):178-81. doi: 10.3760/cma.j.issn.1007-3418.2011.03.007.

[Dynamic changes of Th1/Th2 type cytokines in peripheral blood of patients with hepatitis B e antigen-positive chronic hepatitis B treated with telbivudine].

Zhonghua Gan Zang Bing Za Zhi. 2009 Mar;17(3):175-9.

Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.

Hepatology. 2008 Sep;48(3):759-69. doi: 10.1002/hep.22419.

A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.

Clin Ther. 2010 Apr;32(4):649-58. doi: 10.1016/j.clinthera.2010.04.001.

[Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].

Zhonghua Gan Zang Bing Za Zhi. 2008 Sep;16(9):641-5.

[Clinical antiviral effects of telbivudine in patients with chronic hepatitis B].

Zhonghua Gan Zang Bing Za Zhi. 2010 Apr;18(4):259-62. doi: 10.3760/cma.j.issn.1007-3418.2010.04.006.

Telbivudine for the treatment of chronic hepatitis B.

Drugs Today (Barc). 2007 May;43(5):293-304. doi: 10.1358/dot.2007.43.5.1062671.

引用本文的文献

Current status of drug therapy for chronic hepatitis B.

World J Gastroenterol. 2025 Jan 14;31(2):99443. doi: 10.3748/wjg.v31.i2.99443.

Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index.

BMJ Open Gastroenterol. 2020 Dec;7(1). doi: 10.1136/bmjgast-2020-000543.

Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B.

Front Immunol. 2017 Sep 22;8:1173. doi: 10.3389/fimmu.2017.01173. eCollection 2017.

Comparison of hepatitis B surface antigen and e antigen in predicting liver histology in hepatitis B e antigen-positive chronic hepatitis B patients.

Hepatol Int. 2014 Apr;8(2):216-23. doi: 10.1007/s12072-013-9502-8. Epub 2014 Jan 23.

Role of interleukin-21 in HBV infection: friend or foe?

Cell Mol Immunol. 2015 May;12(3):303-8. doi: 10.1038/cmi.2014.109. Epub 2014 Nov 3.

TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B.

PLoS One. 2014 Feb 14;9(2):e88475. doi: 10.1371/journal.pone.0088475. eCollection 2014.

Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection.

Evol Med Public Health. 2014 Jan;2014(1):1-9. doi: 10.1093/emph/eot023. Epub 2013 Dec 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验